The histidine phosphatase LHPP: an emerging player in cancer. Issue 11 (3rd June 2022)

• Record Type: Journal Article
• Authors: Wu, Fahong; Ma, Hanwei; Wang, Xiaoli; Wei, Hangzhi; Zhang, Wei; Zhang, Youcheng
• Is Part Of: Cell cycle. Volume 21:Issue 11(2022)
• Page Start: 1140
• Page End: 1152
• Publication Date: 2022-06-03
• Subjects: LHPP -- tumor -- target genes -- mechanism; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2022.2044148
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Cancers continue to have high incidence and mortality rates worldwide. Therefore, cancer control remains the main public health goal. Growing research evidence suggests that phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) plays an important role in inhibiting tumor cell progression. It has been reported in the literature that LHPP is expressed at low levels in tumor tissues and cells and that patients with low LHPP expression have a poorer prognosis. Functional studies have shown that LHPP can inhibit tumor cell proliferation, metastasis, and apoptosis by affecting different target genes. In addition, researchers have used iDPP nanoparticles to deliver LHPP plasmids to treat tumors, demonstrating the great potential of LHPP plasmids for cancer therapy. In our review, we highlight the biological functions and important downstream target genes of LHPP in tumors, providing a theoretical basis for the treatment of human cancers. Although not thoroughly studied in terms of tumor mechanisms, LHPP still represents a promising and effective anticancer drug target.